Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.8018
0.023.17%
At close: -
$0.7980
-0.00380-0.47%
After Hours: 7:59 PM EDT
Comments
Loading...
Esperion Therapeutics Analyst Ratings and Price Targets | NASDAQ:ESPR | Benzinga
Esperion Therapeutics Inc has a consensus price target of $5.72 based on the ratings of 10 analysts. The high is $16 issued by HC Wainwright & Co. on April 25, 2025. The low is $2.5 issued by B of A Securities on June 20, 2024. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Needham on May 7, 2025, April 25, 2025, and April 25, 2025, respectively. With an average price target of $8.33 between Needham, HC Wainwright & Co., and Needham, there's an implied 944.28% upside for Esperion Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Goldman Sachs
Citizens Capital Markets
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Esperion Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2025 | Buy Now | 401.25% | Needham | Serge Belanger65% | $5 → $4 | Maintains | Buy | Get Alert |
| 04/25/2025 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2025 | Buy Now | 526.57% | Needham | Serge Belanger65% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2025 | Buy Now | 275.94% | Goldman Sachs | Paul Choi58% | $4 → $3 | Maintains | Neutral | Get Alert |
| 04/08/2025 | Buy Now | 526.57% | Needham | Serge Belanger65% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 401.25% | Citizens Capital Markets | Jason Butler49% | $4 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/04/2025 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 401.25% | JMP Securities | Roy Buchanan35% | $7 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/11/2025 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2025 | Buy Now | 777.19% | JMP Securities | Roy Buchanan35% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/23/2025 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | — | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 401.25% | Goldman Sachs | Paul Choi58% | → $4 | Reinstates | → Neutral | Get Alert |
| 12/17/2024 | Buy Now | 902.51% | Cantor Fitzgerald | Kristen Kluska68% | → $8 | Initiates | → Overweight | Get Alert |
| 12/13/2024 | Buy Now | 651.88% | Needham | Serge Belanger65% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 651.88% | Needham | Serge Belanger65% | $8 → $6 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 902.51% | Needham | Serge Belanger65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 213.28% | B of A Securities | Jason Zemansky69% | $2.9 → $2.5 | Downgrade | Neutral → Underperform | Get Alert |
| 05/22/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/21/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 902.51% | Needham | Serge Belanger65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 902.51% | Needham | Serge Belanger65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 902.51% | Needham | Serge Belanger65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 1905.01% | HC Wainwright & Co. | Joseph Pantginis44% | $22 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 902.51% | Needham | Serge Belanger65% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 213.28% | B of A Securities | Jason Zemansky69% | $4 → $2.5 | Downgrade | Buy → Neutral | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye64% | — | Reinstates | → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 902.51% | Needham | Serge Belanger65% | $9 → $8 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 1027.82% | Needham | Serge Belanger65% | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 1027.82% | Needham | Serge Belanger65% | $10 → $9 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 401.25% | B of A Securities | Jason Zemansky69% | $1.25 → $4 | Upgrade | Underperform → Buy | Get Alert |
| 06/01/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | 1153.13% | Needham | Serge Belanger65% | $12 → $10 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 1403.76% | Needham | Serge Belanger65% | → $12 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 1403.76% | Needham | Serge Belanger65% | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | 275.94% | Morgan Stanley | Jeffrey Hung50% | $9 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/16/2023 | Buy Now | 87.97% | B of A Securities | Jason Zemansky69% | $8 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
| 03/16/2023 | Buy Now | 1403.76% | Needham | Serge Belanger65% | $16 → $12 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 777.19% | Credit Suisse | Judah Frommer65% | $6.5 → $7 | Upgrade | Underperform → Neutral | Get Alert |
| 03/06/2023 | Buy Now | 1779.7% | JMP Securities | Roy Buchanan35% | → $15 | Reiterates | → Market Outperform | Get Alert |
| 03/06/2023 | Buy Now | 1905.01% | Needham | Serge Belanger65% | $12 → $16 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 2656.89% | HC Wainwright & Co. | Joseph Pantginis44% | → $22 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 1027.82% | JP Morgan | Jessica Fye64% | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 902.51% | B of A Securities | Jason Zemansky69% | → $8 | Reinstates | → Neutral | Get Alert |
| 02/22/2023 | Buy Now | 1403.76% | Needham | Serge Belanger65% | → $12 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 1027.82% | Morgan Stanley | Jeffrey Hung50% | → $9 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | 1027.82% | Morgan Stanley | Jeffrey Hung50% | $7 → $9 | Maintains | Underweight | Get Alert |
| 08/03/2022 | Buy Now | 651.88% | Credit Suisse | Judah Frommer65% | $7 → $6 | Downgrade | Neutral → Underperform | Get Alert |
| 07/15/2022 | Buy Now | 777.19% | Morgan Stanley | Jeffrey Hung50% | $5 → $7 | Maintains | Underweight | Get Alert |
| 05/24/2022 | Buy Now | 275.94% | Goldman Sachs | Paul Choi58% | $3.5 → $3 | Maintains | Sell | Get Alert |
FAQ
What is the target price for Esperion Therapeutics (ESPR) stock?
The latest price target for Esperion Therapeutics (NASDAQ:ESPR) was reported by Needham on May 7, 2025. The analyst firm set a price target for $4.00 expecting ESPR to rise to within 12 months (a possible 401.25% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Esperion Therapeutics (ESPR)?
The latest analyst rating for Esperion Therapeutics (NASDAQ:ESPR) was provided by Needham, and Esperion Therapeutics maintained their buy rating.
When was the last upgrade for Esperion Therapeutics (ESPR)?
The last upgrade for Esperion Therapeutics Inc happened on June 15, 2023 when B of A Securities raised their price target to $4. B of A Securities previously had an underperform for Esperion Therapeutics Inc.
When was the last downgrade for Esperion Therapeutics (ESPR)?
The last downgrade for Esperion Therapeutics Inc happened on June 20, 2024 when B of A Securities changed their price target from $2.9 to $2.5 for Esperion Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.
Is the Analyst Rating Esperion Therapeutics (ESPR) correct?
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a maintained with a price target of $5.00 to $4.00. The current price Esperion Therapeutics (ESPR) is trading at is $0.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
